MyAlcon Professional Logo
Online Store
MyAlcon for Consumers

My Alcon | United Kingdom

This page is available in English. Select below for other countries.

Select Another Country

Ophthalmic Viscosurgical Devices (OVDs)

 

Alcon OVDs are trusted and consistent products designed for optimised protection of the cornea, with cohesive and dispersive properties and sufficient volume for every step of the procedure.

Ophthalmic Viscosurgical Devices (OVDs) 


Alcon OVDs are trusted and consistent products designed for optimised protection of the cornea, with cohesive and dispersive properties and sufficient volume for evey step of the procedure.

 

Chondroitin Sulphate Provides Enhanced

Endothelial Coating1-4

Chondroitin sulphate is designed with a double negative charge and when combined with sodium hyaluronate, creates a triple negative charged product. This results in improved adhesion to positively charged endothelial tissue.1-4*

Dark blue circle with the number “-1” in the middle to indicate the charge for sodium hyaluronate. 2 blue interlocking circles both with the numbers “-1” in the middle to indicate chondroitin sulphate’s double negative charge. There is a plus sign between the dark blue circle and the 2 blue interlocking circles to illustrate that when sodium hyaluronate is combined with chondroitin sulphate, a triple negative charge occurs.

* Compared to only-Na-Hyaluronate OVDs

Viscoelastic products containing chondroitin sulphate improve OVD retention.2* 

 

Chondroitin sulphate-containing viscoelastic products demonstrate superior retention and coating of the endothelium under stress from high flow conditions. This leads to less endothelial cell loss and less corneal edema.1-3,5-7

A visual comparison between OVDs that do not contain chondroitin sulphate and OVDs that do contain chondroitin sulphate. The OVDs that do not contain chondroitin sulphate are PROVISC, Healon, Healon 5 and Amvisc. The OVDs that do contain chondroitin sulphate are VISCOAT and DisCoVisc. OVDs with chondroitin sulphate retained 325 µm under high flow while others retained 0 µm.

60 mL/min aspiration rate

 

University of Texas Southwestern Confocal Microscopy in vivo animal study (Adapted by Alcon​; representative CMTF reconstructions​) *Compared to HaNA solutions alone.
† Trademarks are the property of their respective owners.

Alcon’s Viscoat OVD product and product box on a blue circle background.
Alcon’s Viscoat OVD product and product box on a blue circle background.

Viscoat®

Alcon’s DuoVisc OVD product and product box on a blue circle background.
Alcon’s DuoVisc OVD product and product box on a blue circle background.

DuoVisc®

Versatile Performance with DuoVisc®

Viscoelastic System8

3 blue interlocking circles. Inside the first circle white text reads “Pre Phaco.” Inside the middle circle white text reads “Phaco.” Inside the last circle white text reads “IOL Delivery.”

DuoVisc®, as a combination of cohesive and dispersive products, meets each of your procedural needs and preferences to allow a variety of surgical techniques. Following the proven methodology helps to maximise the advantages and minimises the disadvantages of both products.8

 

Range of Volumes to Cover Each Step of the Procedure

 

The required amount of OVD depends on a variety of factors, including the procedure, technique and surgeons’ preference. With this in mind, Alcon OVDs are available in several volumes to fit your needs – even more than 1mL.

Alcon’s DuoVisc OVD product box. This product contains 0.50 ml of Viscoat and 0.55 ml of ProVisc.
Alcon’s DuoVisc OVD product box. This product contains 0.50 ml of Viscoat and 0.55 ml of ProVisc.

Viscoat® 0.50 ml
ProVisc® 0.55ml

Alcon OVDs are Consistent and Trusted by Surgeons9,10

 

Global trust in OVD quality is confirmed by Alcon’s leading market position and surgeon experience. Alcon leads the OVD market with over half of the global revenue share.9,10

Alcon’s DuoVisc OVD product box. This product contains 0.50 ml of Viscoat and 0.55 ml of ProVisc.
Alcon’s DuoVisc OVD product box. This product contains 0.50 ml of Viscoat and 0.55 ml of ProVisc.
Pie chart showing global revenue share from Alcon’s OVDs. 51% of the pie chart is blue, and text in the middle of the chart reads, “Alcon >50% revenue share”. The remaining 49% of the pie chart is divided into multiple grey sections to indicate competitors, all labelled as “others”.
Pie chart showing global revenue share from Alcon’s OVDs. 51% of the pie chart is blue, and text in the middle of the chart reads, “Alcon >50% revenue share”. The remaining 49% of the pie chart is divided into multiple grey sections to indicate competitors, all labelled as “others”.
A white box with text inside that reads “160 million Alcon OVDs used worldwide.” A blue diamond with a white syringe icon inside sits on top of the white box.
A white box with text inside that reads “160 million Alcon OVDs used worldwide.” A blue diamond with a white syringe icon inside sits on top of the white box.

Alcon Experience Academy

 

For relevant training content from industry thought leaders

Visit AEA Portal
    References

    1. Glasser DB, Katz HR, Boyd JE, Shobe SL, Peiffer RL. Protective effects of viscous solutions in phacoemulsification and traumatic lens implantation. Arch Ophthalmol.1989;107(7):1047-1051.
    2. Petroll WM, Jafari M, Lane SS, Jester JV, Cavanagh HD. Quantitative assessment of ophthalmic viscosurgical retention using in vivo confocal microscopy. J Cataract Refract Surg. 2005;31(12):2363-2368.
    3. Poyer JF, Chan KY, Arshinoff SA. New method to measure the retention of viscoelastic agents on rabbit corneal endothelial cell line after irrigation and aaspiration. J Cataract Refract Surg. 1998;24(1):84-90
    4. Lehmann R, Brint S, Stewart R, et al. Clinical comparison of ProVisc® and Healon in cataract surgery. J Cataract Refract Surg. 1995;21(5):543-547.12
    5. Papaconstantinou D, Karmiris T, Diagourtas A, Koutsandrea C, Georgalas I. Clinical trial evaluating Viscoat® and Visthesia ophthalmic viscosurgical devices in corneal endothelial loss after cataract extraction and intraocular lens implantation. Cutan Ocul Toxicol. 2014;33(3):173-180.
    6. Koch D. et al. A comparison of corneal endothelial changes after use of Healon or Viscoat during phacoemulsification. Am J Ophthalmol. 1993;115(2):188-201
    7. Moschos MM, Chatziralli IP, Sergentanis TN. Viscoat versus Visthesia during phacoemulsification cataract surgery: corneal and foveal changes. BMC Ophthalmol. 2011 Apr 29;11:9. doi: 10.1186/1471-2415-11-9. 
    8.Arshinoff SA. Dispersive-cohesive viscoelastic soft shell technique. J Cataract Refract Surg. 1999 Feb;25(2):167-73. doi: 10.1016/s0886-3350(99)80121-7. 
    9. Alcon data on file, REF-14204, 2021.
    10. DisCoVisc® Direction for Use
    11. Alcon Internal Sales Data.

     

    Please refer to the relevant product direction for use for list of indications, contraindications and warnings.

    © 2022 Alcon Inc. 03/22 UKIE-DCV-2200001

    United Kingdom
    Alcon See Brilliantly Logo